Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Allergy Comments on 2019 Proposed PFS

The Advocacy Council of the American College of Allergy, Asthma and Immunology (ACAAI) together with its…

read more

EpiPen Shortage Update

FDA has a drug shortage database which includes reasons for and updates on drug shortages. Today the…

read more

Breaking News on USP Chapter 797

An updated draft of USP Chapter 797 was released today. Updated Chapter 797 Posted for Public Comment: Separate Requirements…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/15/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/26/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course Learn more

07/15/20: Call for Scientific Papers
Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

12/01/20: Research Grant Cycle
Learn more

EDUCATION

New Virtual Course!

Register now as we build out Part 2 Core Allergy & Part 3 Core Rhinology.   Both promise to deliver clinical content you need.  Core Allergy will offer what you need to help refresh or add allergy to your practice — everything from the clinical science to the basics of allergy from a better understanding of testing techniques, vial prep, and dose calculations to other practical implications.  Core Rhinology encompassed the highly sought after rhinology content from our former IAR program.  Part 1 will launch soon with on demand content to help you balance all your time demands.  Part 2 & 3 will feature live-stream content to give you opportunities to interact with the faculty.  Post live session, this content will also be available on demand. Stay tuned for more details as we finish our program build. Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

NEW VIRTUAL COURSE! Core Allergy and Rhinology Concepts: Age of Pandemics and Beyond
Learn How to Reboot Your Practice and Freshen Up on Core Allergy and Rhinology Components
Learn More and Register

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
COVID-19 has made it impossible to convene our 2020 Basic Course. We hope you will consider another AAOA CME opportunity

2020 AAOA Annual Meeting
October 23-25| Scottsdale, AZ
Learn More and Register

2020 Advanced Course in Allergy & Immunology
December 9-12 | Vail, CO
Learn More and Register

AAOA Clinical Insights
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 Basic Course in Allergy & Immunology
July 15-17 | Seattle, WA

News and Updates

Here is What You Missed…

2019 New Orleans was an outstanding success?  With over 500 participants, our AAOA members left…

read more

A Message from AAOA President, Alpen Patel, MD

Alpen Patel, MD, FAAOA is currently serving as 2019-2020 AAOA President. https://www.youtube.com/watch?v=WGGN1HewAsI AAOA's 2019-2020 President,…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Menu

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in AMA gives us a voice.

The American Medical Association is one organization that the AAOA works through to advocate for issues related to the AAOA.   As a national specialty society, your membership in the AMA is what gives us our seat — which gives us a voice on your behalf.  This seat goes beyond our AMA House of Delegates delegation.  It gives us a seat at CPT, RUC, and PERC as well.   Without a seat in the AMA, we would not be able to participate in these other regulatory bodies.

Through our involvement in the AMA, we have been able to collaborate with AAAAI and  ACAAI to oppose change in the proposed changes to USP 797 concerning physician allergy compounding that was put forth 2 years ago.  Those joint efforts resulted in halting the change in USP policy and causing USP to revamp recommendations. USP 797 and issues around physician compounding at the FDA are key examples of issues where AAOA’s participation in national coalitions and working with AMA have been instrumental in helping to assure you can deliver quality care.

Through this advocacy effort and the work of our Socioeconomic Committee, we were invited two years ago by the ACAAI leadership to participate on its Advocacy Council of the ACAAI.  Again, broadening our voice and impact on allergy patient care.

Our AMA seat does broaden our opportunities in the House of Medicine.  Networking is key in managing issues at the AMA.  Your AAOA delegation is actively involved in the Chest/Allergy Caucus.  In fact, we will chair this caucus beginning in 2019.  This caucus brings together all the specialties involved in airway management — Chest, Thoracic, Sleep, Allergy, Critical Care, and Pulmonology.  In the House, this caucus has been instrumental in joining forces on issues around physician compounding, tobacco, allergy, food allergy and labeling, over-the-counter medications, and many others.

We also sit on the Otolaryngology Section Council with our peer societies within otolaryngology — AAOHNS, AAFPRS, Triologic, and now ARS — as well as all the otolaryngologists who represent their states in the House of Medicine.  Coalescing these key delegates helps assure specialty interests and state interests are considered together to help achieve better results.

As a specialty society in the AMA House, we have a seat in the Specialty and Service Section, which gives us the opportunity for multiple specialty societies to unite on issues.

The AMA 2018 Interim House of Delegates meeting is just ending in Washington, DC.   Several key issues tied to tobacco, food allergy, CMS, E/M coding, CHIP reauthorization, and more were considered.  The Chest/Allergy caucus was effective in bringing an emergency resolution regarding the FDA’s recent (11/6) decision to put Primatene Mist, an antiquated medication, back on the market as an over-the-counter product to treat mild and intermittent asthma.  While originally pulled due to its delivery mechanism impacting the ozone layer, Primatene Mist, a nonspecific beta agonist or epinephrine, has not been defined as a therapeutic pathway of choice for the management of asthma in any national or international  asthma guideline.  Risk of patient self medication, cardio-vascular risk, and payor issues were all flagged as potential bad, unintended outcomes of pushing Primatene Mist back on the market.  Additionally, issues were raised regarding the FDA process and lack of a public comment period to allow for input, and the AMA will take action with the FDA to urge them to reconsider their decision.

So while you may not always agree with the AMA on issues or want to add yet another dues to your professional costs, our seat is tied to our membership numbers in AMA.  Specialty societies are required to have at least a 20% AMA membership to have a seat.  Your membership in AMA gives us a voice — both on issues with which we agree with AMA and those with which we do not.  Please consider becoming a member of the AMA so we can maintain our seat in the AMA in 2019.

Wes VanderArk, MD, FAAOA
AAOA AMA Delegate